Overcoming sink limitations in dissolution testing: A review of traditional methods and the potential utility of biphasic systems

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 11, 2012, Pages 1549-1559

  Phillips, Daniel J ^a   Pygall, Samuel R ^b   Cooper, V Brett ^b   Mann, James C ^b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b MSD   (United Kingdom)

Author keywords

biphasic; dissolution; poor solubility

Indexed keywords

ALCOHOL; ATOVAQUONE; CETRIMIDE; CHLOROFORM; COCAMIDOPROPYL BETAINE; DIPYRIDAMOLE; DISODIUM HYDROGEN PHOSPHATE; DODECYL SULFATE SODIUM; FLIBANSERIN; N [4 [6 [4 (TRIFLUOROMETHYL)PHENYL] 4 PYRIMIDINYLOXY]BENZOTHIAZOL 2 YL]ACETAMIDE; NIFEDIPINE; OCTANOL; ORGANIC SOLVENT; PHENACETIN; POLYSORBATE 80; SOLVENT;

BIPHASIC DISSOLUTION SYSTEM; CHEMICAL PARAMETERS; DISSOLUTION MEDIUM; DISSOLUTION TEST; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG INDUSTRY; DRUG SOLUBILITY; MATERIALS; MODEL; REVIEW; SATURATION; SINK CONDITION; USP APPARATUS I; USP APPARATUS II;

CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG INDUSTRY; MODELS, CHEMICAL; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 84867571836     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01523.x     Document Type: Review

References (75)

1. Banakar UV, Block LH,. Beyond bioavailability testing. Pharm Technol 1983; 7: 107-117.
2. Löbenberg R, et al,. Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm Res 2000; 17: 439-444.
3. Dyas AM, Shah UU,. Dissolution and dissolution testing. In:, Swarbrick J, ed. Encyclopedia of Pharmaceutical Technology, Vol. 1, 3rd edn. New York: Informa Healthcare USA, Inc., 2007: 908-928.
4. Dressman JB, et al,. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998; 15: 11-22.
5. Shah VP, Williams RL,. Roles of dissolution testing: regulatory, industry and academic perspectives: role of dissolution testing in regulating pharmaceuticals. Dissolution Technol 1999; 8: 7-10.
6. Pillay V, Fassihi R,. Unconventional dissolution methodologies. J Pharm Sci 1999; 88: 843-851.
7. Noyes AW, Whitney WR,. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1897; 19: 930-934.
8. Brunner L, Tolloczko S,. Über die Auflösungsgeschwindigkeit Fester Körper. Z Phys Chem 1900; 35: 282-290.
9. Dokoumetzidis A, Macheras P,. A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system. Int J Pharm 2006; 321: 1-11.
10. The dissolution procedure. United States Pharmacopeia and National Formulary USP32-NF27. Rockville, MD: The United States Pharmacopeial Convention, Inc., 2009: 601.
11. Brown CK, et al,. Acceptable analytical practices for dissolution testing of poorly soluble compounds. Pharm Technol 2004; 28: 56-65.
12. Gowthamarajan K, Singh SK,. Dissolution testing for poorly soluble drugs: a continuing perspective. Dissolution Technol 2010; 17: 24-33.
13. Amidon GL, et al,. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420.
14. Yu LX, et al,. Biopharmaceutics classification system: the scientific basis for biowaver extensions. Pharm Res 2002; 19: 921-925.
15. Ku MS,. Use of the biopharmaceutical classification system in early drug development. AAPS J 2008; 10: 208-212.
16. Wilson WI, et al,. Comparison of statistical analysis and bayesian networks in the evaluation of dissolution performance of BCS class II model drugs. J Pharm Sci 2005; 94: 2764-2776.
17. Jamzad S, Fassihi R,. Role of surfactant and pH on dissolution properties of fenofibrate and glipizide-a technical note. AAPS PharmSciTech 2006; 7: E33.
18. Lee J, et al,. Surfactant effects upon dissolution patterns of carbamazepine immediate release tablets. Arch Pharm Res 2005; 28: 120-126.
19. Shah VP, et al,. In vitro dissolution of sparingly water-soluble drug dosage forms. Int J Pharm 1995; 125: 99-106.
20. Corrigan OI, Healy AM,. Surfactants in pharmaceutical products and systems. In:, Swarbrick J, ed. Encyclopedia of Pharmaceutical Technology, Vol. 5, 3rd edn. New York: Informa Healthcare USA, Inc., 2007: 3583-3596.
21. Rangel-Yagui CO, et al,. Micellar solubilization of drugs. J Pharm Pharm Sci 2005; 8: 147-163.
22. Söderlind E, et al,. The usefulness of sugar surfactants as solubilizing agents in parenteral formulations. Int J Pharm 2003; 252: 61-71.
23. Nagarajan R, Ruckenstein E,. Theory of surfactant self-assembly: a predictive molecular thermodynamic approach. Langmuir 1991; 7: 2934-2969.
24. Heng PWS, et al,. Role of surfactant on drug release from tablets. Drug Dev Ind Pharm 1990; 16: 951-962.
25. Hanaee J, et al,. The role of various surfactants on the release of salbutamol from suppositories. Farmaco 2004; 59: 903-906.
26. Allaboun H, et al,. Effect of surfactant on dissolution of spherical particles in micellar systems. Eur J Pharm Biopharm 2007; 65: 188-197.
27. Ruddy SB, et al,. Design and characterization of a surfactant-enriched tablet formulation for oral delivery of a poorly water-soluble immunosuppressive agent. Int J Pharm 1999; 182: 173-186.
28. Chen LR, et al,. Dissolution behavior of a poorly water soluble compound in the presence of tween 80. Pharm Res 2003; 20: 797-801.
29. Qazi S, et al,. Evaluating dissolution profiles of an anti-HIV agent using ANOVA and non-linear regression models in JMP software. Int J Pharm 2003; 252: 27-39.
30. Nilsson S,. Interactions between water-soluble cellulose derivatives and surfactants. 1. The HPMC/SDS/Water System. Macromolecules 1995; 28: 7837-7844.
31. Saito S,. Binding of surfactants by polymers. J Colloid Sci 1960; 15: 282-286.
32. Daly PB, et al,. The effect of anionic surfactants on the release of chlorpheniramine from a polymer matrix. Int J Pharm 1984; 18: 201-205.
33. Alli D, et al,. Hydroxypropylmethylcellulose-anionic surfactant interactions in aqueous systems. J Appl Polym Sci 2003; 42: 947-956.
34. Katchen B, Symchowicz S,. Correlation of dissolution rate and griseofulvin absorption in man. J Pharm Sci 1967; 56: 1108-1111.
35. Symchowicz S, Katchen B,. Griseofulvin absorption in man after single and repeated treatment and its correlation with dissolution rates. J Pharm Sci 1968; 57: 1383-1386.
36. Chiou WL, Riegleman S,. Oral absorption of griseofulvin in dogs: increased absorption via solid dispersion in polyethylene glycol 6000. J Pharm Sci 1970; 59: 937-942.
37. Goehl TJ, et al,. Analytical methodology applicable in dissolution testing of norethindrone-mestranol tablets. Int J Pharm 1982; 11: 181-186.
38. Strickley RG,. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004; 21: 201-230.
39. Corrigan OI,. Co-solvent systems in dissolution testing: theoretical considerations. Drug Dev Ind Pharm 1991; 17: 695-708.
40. Liu C, et al,. Solubility of rofecoxib in the presence of aqueous solutions of glycerol, propylene glycol, ethanol, span 20, tween 80 and sodium lauryl sulfate at (298.15, 303.15 and 308.15) K. J Chem Eng Data 2005; 50: 2061-2064.
41. Khoo S-M, et al,. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm 1998; 167: 155-164.
42. Walkling WD, et al,. A partially organic dissolution medium for griseofulvin dosage forms. Drug Dev Ind Pharm 1979; 5: 17-27.
43. El-Massik MA, et al,. Development of a dissolution medium for glibenclamide. Int J Pharm 1996; 140: 69-76.
44. Fotaki N,. Flow-through cell appartus (USP apparatus 4): operation and features. Dissolution Technol 2011; 18: 46-49.
45. Butler WCG, Bateman SR,. A flow-through dissolution method for a two-component drug formulation where the actives have markedly differing solubility properties. Int J Pharm 1998; 173: 211-219.
46. Garbacz G, Klein S,. Dissolution testing of oral modified-release dosage forms. J Pharm Pharmacol 2012. doi: 10.1111/j.2042-7158.2012.01477.x.
47. Nicklasson M, et al,. A collaborative study of the in vitro dissolution of phenacetin crystals comparing the flow through method with the USP paddle method. Int J Pharm 1991; 69: 255-264.
48. Brown W,. Apparatus 4 flow through cell: some thoughts on operational characteristics. Dissolution Technol 2005; 12: 28-32.
49. Posti J, Speiser PP,. Sink conditions in the flow-through cell during dissolution. Int J Pharm 1980; 5: 101-107.
50. Quershi SA, et al,. Application of flow-through dissolution method for the evaluation of oral formulations of nifedipine. Drug Dev Ind Pharm 1994; 20: 1869-1882.
51. Kakhi M,. Classification of the flow regimes in the flow-through cell. Eur J Pharm Sci 2009; 37: 531-544.
52. Grundy JS, et al,. Studies on dissolution testing of the nifedipine gastrointestinal therapeutic system. I. Description of a two-phase in vitro dissolution test. J Control Release 1997; 48: 1-8.
53. Levy G,. Papers Presented Before the Industrial Pharmacy Section. American Pharmaceutical Association: Dallas Meeting; 1966, pp 233-252.
54. Gibaldi M, Feldman S,. Establishment of sink conditions in dissolution rate determinations. J Pharm Sci 1967; 56: 1238-1242.
55. Hoa NT, Kinget R,. Design and evaluation of two-phase partition-dissolution method and its use in evaluating artemisinin tablets. J Pharm Sci 1996; 85: 1060-1063.
56. Ngo TH, et al,. Dissolution testing of artemisinin solid oral dosage forms. Int J Pharm 1996; 138: 185-190.
57. Ungell A-L,. In vitro absorption studies and their relevance to absorption from the GI tract. Drug Dev Ind Pharm 1997; 23: 879-892.
58. Rothwell JA, et al,. Experimental determination of octanol-water partition coefficients of quercetin and related flavonoids. J Agric Food Chem 2005; 53: 4355-4360.
59. Wohnsland F, Faller B,. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem 2001; 44: 923-930.
60. Vangani S, et al,. Dissolution of poorly water-soluble drugs in biphasic media using USP 4 and fiber optic system. Clin Res Regul Aff 2009; 26: 8-19.
61. Polli JE, et al,. Novel approach to the analysis of in vitro-in vivo relationships. J Pharm Sci 1996; 85: 753-760.
62. Mauger DT, Chinchilli VM,. In vitro -in vivo relationships for oral extended-release drug products. J Biopharm Stat 1997; 7: 565-578.
63. Heigoldt U, et al,. Prediciting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test. Eur J Pharm Biopharm 2010; 76: 105-111.
64. Chaudhary RS, et al,. Dissolution system for nifedipine sustained release formulations. Drug Dev Ind Pharm 1994; 20: 1267-1274.
65. Lindenberg M, et al,. Classification of orally administered drugs on the world health organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004; 58: 265-278.
66. Ali SL,. Nifedipine. In:, Florey K, ed. Analytical Profiles of Drug Substances, Vol. 18. New York: Academic Press, 1989: 221-288.
67. Boje KM, et al,. Complexation of nifedipine with substituted phenolic ligands. Pharm Res 1988; 5: 655-659.
68. Uehara A, Hume JR,. Interactions of organic calcium channel antagonists with calcium channels in single frog atrial cells. J Gen Physiol 1985; 85: 621-647.
69. 2+. Eur J Pharmacol 1999; 366: 309-317.
70. Navia MA, Chaturvedi PR,. Design principles for orally bioavailable drugs. Drug Discov Today 1996; 1: 179-189.
71. Grundy JS, et al,. Studies on dissolution testing of the nifedipine gastrointestinal therapeutic system. II. Improved in vitro-in vivo correlation using a two-phase dissolution test. J Control Release 1997; 48: 9-17.
72. Phillips DJ, et al,. Towards biorelevant dissolution: an application of a biphasic dissolution model as a discrimination tool for HPMC matrices containing a model BCS class II drug. Dissolution Technol 2012; 19: 25-34.
73. Levina M, et al,. The influence of hydro-alcoholic media on hypromellose matrix systems. Drug Dev Ind Pharm 2007; 33: 1125-1134.
74. Galia E, et al,. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 1998; 15: 698-705.
75. Pouton CW,. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 2006; 29: 278-287.